MétaCan
Menu
Back to cohort
Record W2329976634 · doi:10.1158/1538-7445.am2011-4108

Abstract 4108: BH3 only Bcl-2 family member BNIP3 repressed expression of death receptor 5 (DR5) in glioblastoma cells: Implications for regulation of the tumor necrosis factor related apoptosis inducing ligand (TRAIL) cell death pathway

2011· article· en· W2329976634 on OpenAlexaff
Elizabeth S. Henson, Teralee Burton, Meghan B. Azad, David D. Eisenstat, Spencer B. Gibson

Bibliographic record

VenueCancer Research · 2011
Typearticle
Languageen
FieldImmunology and Microbiology
Topicinterferon and immune responses
Canadian institutionsUniversity of Manitoba
Fundersnot available
KeywordsApoptosisProgrammed cell deathCancer researchTumor necrosis factor alphaTemozolomideGliomaBiologySmall hairpin RNAReceptorChemistryImmunologyGenetics

Abstract

fetched live from OpenAlex

Abstract Glioblastoma multiforme (GBM) is the most aggressive form of brain cancer. The median survival for patients with GBM is less than 15 months, even with treatment such as surgery, radiation and chemotherapy with temozolomide. Resistance to the standard treatment regimes represents a serious clinical challenge. GBM tumors contain extensive regions of necrosis, indicative of hypoxia. BNIP-3 (Bcl-2 nineteen kilodalton interacting protein) is a BH-3 only, pro-cell death member of the Bcl-2 family. BNIP-3 is up-regulated in hypoxia and leads to a non-classical programmed cell death through the mitochondria. In the majority of glioblastoma multiforme tumors, BNIP3 is localized to the nucleus and does not induce cell death. Our group has shown that when located in the nucleus, BNIP3 binds to DNA including the promoters of cell death genes such as AIF (apoptosis inducing factor). Herein, we found that BNIP3 bound to the promoter region of death receptor 5 (DR5). DR5 binds to the tumor necrosis factor related apoptosis inducing ligand (TRAIL) leading to induction of apoptosis. TRAIL is currently in phase 2 clinical trials for a wide variety of tumor types but glioblastoma tumors are resistant to TRAIL induced apoptosis. Our data showed that binding of BNIP3 to the promoter of DR5 prevented its expression and led to resistance to TRAIL induced cell death in glioma cells. Furthermore, when a BNIP3 construct was transiently over-expressed in the nucleus, DR5 mRNA and protein levels were reduced; also when BNip3 was knocked down using shRNA, DR5 message and protein levels increased. In BNIP3 knockout mice, we demonstrated that increased DR5 levels were increased in primary astrocytes compared to wild type controls as detected by western blot and immunofluorescence. We also showed similar results in brain sections from BNIP3 knockout mice. In paraffin embedded GBM tumors, we found that tumors that had BNIP3 in the nucleus had decreased levels of DR5, whereas tumors without BNIP3 in the nucleus had higher levels of DR5. Taken together, this represents a novel mechanism for regulation of DR5 expression, contributing to TRAIL resistance in GBM tumors. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 4108. doi:10.1158/1538-7445.AM2011-4108

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.000
metaresearch head score (Gemma)0.000
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Bench or experimental · Consensus signal: Bench or experimental
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.003
Threshold uncertainty score0.011

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0000.000
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0000.000
Bibliometrics0.0000.000
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.001
Insufficient payload (model declined to judge)0.0030.001

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.086
GPT teacher head0.332
Teacher spread0.245 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designBench or experimental
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2011
Admission routes1
Has abstractyes

Explore more

Same venueCancer ResearchSame topicinterferon and immune responsesFrench-language works237,207